

Minutes of the 237th(overall) and 105th meeting of the Authority under DPCO, 2013 held on 15.12.2022 at 03:30 PM

The 237th meeting of the Authority (overall), which is the 105th meeting under the DPCO, 2013, was held on 15th December at 03:30 PM under the Chairmanship of Shri Kamlesh Kumar Pant, Chairman, NPPA. The following Authority members of NPPA were present during the meeting:

- (i) Dr. Vinod Kotwal, Member Secretary, NPPA
- (ii) Shri G. Venkatesh, Adviser (Cost), O/o Chief Adviser (Cost), Department of Expenditure
- (iii) Shri Saikat Sarkar, Economic Adviser, Department of Economic Affairs-joined through video-conferencing

Shri A. K. Pradhan, Jt. Drug Controller, CDSCO, Ministry of Health & Family Welfare also was present.

1.1 The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Shri Manmohan Sachdeva, Advisor (Cost-I)
- (ii) Shri Sanjay Kumar, Advisor (Cost-II)
- (iii) Shri G.L. Gupta, Director (M&E/A)
- (iv) Ms. Rashmi Tahiliani, Joint Director (Pricing)
- (v) Shri Saurabh Bansal, DD (M&E)
- (vi) Shri Mahaveer Saini, Deputy Director (Pricing)
- (vii) Ms. Yuvika Panwar, Assistant Director (Overcharging/Pricing)

II. Agenda items

1. Agenda item no. 1 - Confirmation of Minutes of the 104th Meeting held on 23.11.2022

1.1 The Authority confirmed the minutes without any change.

2. Agenda item no. 2 - (a) Action Taken Report (ATR) on decisions taken by NPPA in its 104th Meeting held on 23.11.2022

2.1 Noted.

3. Agenda item no. 3 - Status of New Drug applications

3.1 Noted.

4. Agenda item no. 4 – New Drug applications for Price fixation under Para 5 and Para 15 of DPCO, 2013

4.1The Authority discussed the following cases of retail pricefixation of new drugs as presented in Agenda no. 4 (i) to 4 (x)(total 10 Form I applications containing retail price fixation of 10 new drug) falling under the purview of Para 2(1)(u) of DPCO, 2013 and approved the retail prices of 10(Ten) new drugs under Para 5 and 15 of the DPCO 2013, as detailed below:

S. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Amoxicillin and Potassium Clavulanate Oral Suspension IP	Each Combipack contains: (A) Amoxicillin and Potassium Clavulanate Oral Suspension IP Composition: Each 5ml of Reconstituted suspension contains: Amoxicillin Trihydrate IP eq. to Amoxicillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg (B) 2 Ampoule of Sterile Water for Reconstitution of Dry Syrup Each Ampoule Contains: Sterile Water for Injections IP 25ml	Combi Pack (50ml)	M/s Malik Lifesciences Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	168.43
2.	Metformin Hydrochloride (SR), Glimepiride and Voglibose Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 1000mg (In Sustained Release form) Glimepiride IP 1mg Voglibose IP 0.2mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd.	11.60
3.	Metformin Hydrochloride (SR), Glimepiride and Voglibose Tablets	Each uncoated bilayered tablet contains: Metformin Hydrochloride IP 1000mg (In Sustained Release form) Glimepiride IP 2mg Voglibose IP 0.2mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd.	13.18
4.	Ceftazidime and Avibactam	Each vial contains: Ceftazidime	Per Vial	M/s Cipla Limited	

S. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
	powder for concentrate for solution for infusion	(pentahydrate) IP eq. to Ceftazidime 2mg Avibactam Sodium eq. to Avibactam 0.5gm Sodium content approx. 148mg (6.4meq)/vial			2500.00
5.	Moxifloxacin Hydrochloride and Loteprednol Ophthalmic Suspension	Composition: Moxifloxacin Hydrochloride IP eq. to Moxifloxacin 0.5% w/v Loteprednol Etabonate 0.5% w/v (Steril& Micronized) Sterile aqueous buffered vehicle q.s.	Per ml	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Cipla Limited	27.43
6.	Itraconazole Capsules 65mg (Supra-Bioavailable Formulation)	Each hard gelatin capsule contains: Itraconazole BP 65mg	1 Capsule	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd.	11.60
7.	Acetylsteyne& Acebrophylline Tablets	Each film coated tablet contains: Acetylcysteine BP 600mg Acebrophylline 100mg	1 Tablet	M/s Pure and Care Healthcare Pvt. Ltd. / M/s Cadila Pharmaceuticals Limited	14.91
8.	Paracetamol, Phenylephrine Hydrochloride, Caffeine & Dipphenhydramine Hydrochloride Tablets	Each uncoated tablet contains: Paracetamol IP 500mg Phenylephrine HCl IP 5mg Caffeine IP 30mg Diphenhydramine HCl IP 25mg	1 Tablet	M/s Dallas Drugs Pvt. Ltd. / M/s Micro Labs Pvt. Ltd.	2.76
9.	Rabeprazole and Ondansetron tablets	Each Enteric coated tablet contains: Rabeprazole Sodium IP 20mg Ondansetron Hydrochloride eq. to Ondansetron IP 4mg	1 Tablet	M/s Dallas Drugs Pvt. Ltd. / M/s Micro Labs Pvt. Ltd.	5.90
10.	Amoxycillin and Potassium Clavulanate Oral Suspension IP	Each 5ml of Reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg	Per Vial (50ml)	M/s Malik Lifesciences Pvt. Ltd. / M/s Zuventus Healthcare Limited	168.43

5. Agenda item no. 5 – Status of implementation of Review cases

5.1 Noted.

6. Agenda item no. 6-Proposed Framework for undertaking Suo Moto corrections in the notified prices by NPPA.

6.1 Fixation of ceiling prices of scheduled formulations and retail prices of new drugs is done based on the market based data as per the methodology laid down in DPCO, 2013. The source of market base data at present is the Pharmatrac database provided by AIOCD-AWACS on a monthly basis, which is an independent third party that provides the market-based data to NPPA as per the terms of contract entered into with it.

6.2 The draft working sheets for fixation of prices are uploaded on NPPA website to invite comments from the affected companies/ any person in compliance to DoP's O.M. dated 11.07.2016. If no comments are received within 10 working days, the prices as proposed in draft working sheets are placed for approval by the Authority. Once approved, the prices are notified by a Gazette notification.

6.3 NPPA has come across, few cases of data inconsistency/errors in the Pharmatrac data base, which normally fall under the following categories:

- i. Error in pack size of formulations, for example, pack of 4 medicines shown as 1 in database.
- ii. Formulations apparently not available in a relevant subgroup but recorded under a separate subgroup by Pharmatrac and price fixed by NPPA ignoring item(s) in that other subgroup.
- iii. Wrong PTR reported in Pharmatrac (for example, PTR higher than MRP appearing on web sources) and later on the same is rectified by Pharmatrac
- iv. Typographical error etc.

6.4 The above inconsistency/ errors may not be always ascertainable at the time of calculation of the prices despite exercising appropriate rigorous verification process. Therefore, prices are fixed based on available data and in case, no representation is received, the prices after approval by the Authority are notified.

6.5 Where any data inconsistency/errors are identified while fixing the prices of any formulation, NPPA also looks at the working sheets for the prices fixed for the same formulation in the recent past. While undertaking such exercise, NPPA may come across data inconsistency/errors that might have occurred in the past.

6.6 These have to be rectified as the primary function of NPPA is to ensure that pricing of the formulations is done correctly as per the provisions of DPCO. It is also in the

public interest to ensure that the drugs are priced correctly so as to avoid their overpricing/ underpricing. DPCO, 2013 also does not prohibit NPPA from taking any corrective action once an error is noticed. The opinion of Legal Division, NPPA was also sought in this matter.

6.7 After detailed deliberations, the authority decided that Suo Moto action may be taken by NPPA for carrying out corrections even after the notification of prices only in the following cases:

- a. Where such errors are duly acknowledged by Pharmatrac and/or correct data is confirmed from the companies.
- b. There is no deviation from the pricing methodologies being followed by NPPA.
- c. No review proceeding is pending for the subject formulation.

6.8 The corrected working sheet shall be uploaded on NPPA website for 10 working days for comments, if any. In case of non-receipt of any comments or after addressing any issues received on the revised working sheets, the same shall be placed before the Authority for decision. In those cases where the data has been verified and confirmed by Pharmatrac, prices will be re-computed based on revised data. Accordingly, corrigendum/ addendum/new price notifications will be issued.

6.9 The Authority agreed to the above framework and based on the detailed discussions also noted that such instances/cases would be few. However, utmost care must be exercised while processing such cases including verification of data. It was also noted that such rectifications may either lead to upward or downward revision of prices.

7. Agenda item no. 7 -Form-IV intimation received from M/s Serum Institute of India Pvt. Ltd in respect of 2 scheduled formulations (1) Tetanus Toxoid Injection 0.5ml and (ii) Tetanus Toxoid Injection 5 ml of M/s Serum Institute of India Pvt. Ltd-reg.

7.1 The Authority noted that directions under Para 3 of DPCO, 2013 were issued to M/s Serum Institute of India Pvt. Ltd. from time to time by the Authority for continued production/ sale in respect of 2 scheduled formulations (i) Tetanus Toxoid Injection in 0.5ml pack and (ii) Tetanus Toxoid Injection in 5 ml pack manufactured by M/s Serum Institute of India Pvt. Ltd. The period of continuation of production/ sale was extended up to 22.12.2022 in the 99th Authority meeting held on 28.06.2022.

7.2 The Authority deliberated upon the matter in detail and decided to re-invoke Para 3 of DPCO, 2013 to direct M/s Serum Institute of India Pvt. Ltd to continue the production and sales of 2 scheduled formulations (1) Tetanus Toxoid Injection in 0.5ml pack and (ii) Tetanus Toxoid Injection in 5 ml pack up to 31.12.2023.

8. Agenda item no. 8-Fixation of Ceiling Price of scheduled formulations under Revised Schedule-I (NLEM, 2022).

8.1 The methodology for fixation of ceiling price of scheduled formulations under revised Schedule-I (NLEM, 2022) was deliberated in the 104th meeting of Authority held on 23.11.2022. Based on methodology approved, ceiling prices for 121 formulations were uploaded on NPPA website on 25.11.2022 for 10 working days to invite comments in compliance to O.M. No. F. NO. 31015/44/2016-PI.I dated 11.07.2016 issued by Department of Pharmaceuticals. The last date for receiving the representations for these 121 formulations was 09.12.2022.

8.2 The Authority was apprised that till 9.12.2022, 267 representations from companies were received for 91 formulations out of 121 formulations uploaded on 25.11.2022. Companies have submitted copy of invoice showing the revised PTR and snapshots of sample pack showing revised MRP. It was informed that these representations can be broadly categorized as under:

(a) Related to data in worksheets:

- i. Price to Retailer considered as per July, 2022 Pharmatrac database is not reflecting the WPI increase availed by the companies in April, 2022;
- ii. Incorrect pack sizes; and
- iii. Considering MR variant along with conventional variant in cases where MR variant is separately included in schedule.

(b) Related to methodology:

- i. Representations on methodology mainly relating to using July, 2022 database;
- ii. Consideration of all variant for pricing of drugs i.e. SR, ER, PR etc.;
- iii. 16% retailer margin is considered for fixation of ceiling prices whereas the industry practice is to allow 20% margin on MRP etc.; and
- iv. Prices of formulation which were increased under Para 19 like Heparin, Metronidazole, etc. and period of 5 years has not lapsed since such revision should not be considered for ceiling price fixation.

8.3 The Authority noted that the issues related to methodology as per the representations have been already deliberated and decided in 104th meeting of the authority. However, with regard to representations related to data, the Authority was informed that the claims made by the companies in their representations have been cross verified with the Form-II/Form-V submitted by the companies till 15.05.2022 in IPDMS as per provisions of DPCO, 2013. As result there was price revision in 69 formulations as compared to the ceiling prices reflected in the draft uploaded working sheets.

8.4 The Authority also noted the representation of M/s Glenmark Pharmaceuticals Limited dated 07.12.2022 stating that their product is capsule and not tablet in respect of two formulations i.e. Dabigatran 110 mg (Tablets) and Dabigatran 150 mg (Tablets). It was also informed that the same has been confirmed with Pharmatrac and web sources. Only one company is qualifying with MAT of more than 1% in respect of two formulations i.e. Dabigatran 110 mg (Tablets) and Dabigatran 150 mg (Tablets). Hence, the case falls under Para 6 of DPCO, 2013 for calculation of ceiling price by applying monopoly clause. Therefore, the matter of fixation of ceiling prices of two formulations i.e. Dabigatran 110 mg (Tablets) and Dabigatran 150 mg (Tablets) is deferred.

8.5 The Authority deliberated and approved the ceiling prices of 119 formulations as appearing in column (7) of the Table below:

S.No (1)	Section of revised Schedule-I (2)	Formulation (3)	Dosage form(s) and strength(s) (4)	Prevailing Ceiling Price		New Ceiling Price With immediate effect (7)	Unit (8)
				Rs./Unit (5)	SO No. & dated (6)		
				1	2.1.5		
2	2.3.1	Allopurinol	Tablet300mg	8.31	(S.O. 1499(E) dated 30.03.2022)	5.02	Per Tablet
3	2.4.2	Hydroxychloroquine	Tablet400mg	13.26	(S.O. 1499(E) dated 30.03.2022)	12.31	Per Tablet
4	5.1.1	Carbamazepine	Modified Release – Tablet200mg	2.59	(S.O. 1499(E) dated 30.03.2022)	2.14	Per Tablet
5	5.1.1	Carbamazepine	Modified Release – Tablet400mg	5.11	(S.O. 1499(E) dated 30.03.2022)	4.16	Per Tablet
6	5.1.1	Carbamazepine	Tablet400mg	3.67	(S.O. 1499(E) dated 30.03.2022)	3.17	Per Tablet
7	5.1.2	Clobazam	Tablet5mg	5.7	(S.O. 1499(E) dated 30.03.2022)	4.94	Per Tablet
8	5.1.2	Clobazam	Tablet10mg	10.04	(S.O. 1499(E) dated 30.03.2022)	8.55	Per Tablet
9	5.1.4	Levetiracetam	Tablet250mg	6.49	(S.O. 1499(E) dated 30.03.2022)	5.57	Per Tablet
10	5.1.4	Levetiracetam	Tablet500mg	13.13	(S.O. 1499(E) dated 30.03.2022)	11.4	Per Tablet
11	5.1.4	Levetiracetam	ModifiedReleaseTablet750mg	19.31	(S.O. 1499(E) dated 30.03.2022)	16.32	Per Tablet
12	5.1.4	Levetiracetam	Tablet750mg	20.19	(S.O. 1499(E) dated 30.03.2022)	16.98	Per Tablet
13	5.1.5	Lorazepam	Tablet1 mg	2.29	(S.O. 1499(E) dated 30.03.2022)	2.06	Per Tablet
14	5.1.5	Lorazepam	Tablet2 mg	2.79	(S.O. 1499(E) dated 30.03.2022)	2.51	Per Tablet
15	5.1.10	SodiumValproate	Tablet300mg	4.41	(S.O. 1499(E) dated 30.03.2022)	3.98	Per Tablet
16	6.1.1.2	Mebendazole	Tablet100 mg	3.26	(S.O. 1499(E) dated 30.03.2022)	2.59	Per Tablet
17	6.1.2.2	Diethylcarbamazine(DEC)	Tablet100mg	1.57	(S.O. 1499(E) dated 30.03.2022)	1.49	Per Tablet
18	6.2.1.6	Cefadroxil	Tablet500mg	4.47	(S.O. 1499(E) dated 30.03.2022)	3.99	Per Tablet
19	6.10.1.1	Artemether (A)	Tablet80mg(A)+480mg(B)	25.72	(S.O. 1499(E) dated	22.75	Per

S.No	Section of revised Schedule-I	Formulation	Dosage form(s) and strength(s)	Prevailing Ceiling Price		New Ceiling Price With immediate effect	Unit
				Rs./Unit	SO No. & dated		
				(5)	(6)		
		+Lumefantrine(B)			30.03.2022)		Tablet
20	6.10.1.1	Artemether (A) +Lumefantrine(B)	Tablet 20 mg (A) + 120 mg (B)	13.9	(S.O. 1499(E) dated 30.03.2022)	11.28	Per Tablet
21	6.2.1.8	Cefixime	Tablet400mg	24.5	(S.O. 1499(E) dated 30.03.2022)	19.71	Per Tablet
22	6.2.2.4	Clarithromycin	Tablet250mg	31.09	(S.O. 1499(E) dated 30.03.2022)	21.04	Per Tablet
23	6.2.2.4	Clarithromycin	Tablet500mg	54.8	(S.O. 1499(E) dated 30.03.2022)	34.61	Per Tablet
24	6.4.5	Cycloserine	Capsule250mg	60.28	(S.O. 1499(E) dated 30.03.2022)	52.79	Per Capsule
25	6.4.8	Ethionamide	Tablet250mg	17.52	(S.O. 1499(E) dated 30.03.2022)	13.21	Per Tablet
26	6.4.10	Levofloxacin	Tablet250mg	4.9	(S.O. 1499(E) dated 30.03.2022)	4.25	Per Tablet
27	6.4.10	Levofloxacin	Tablet500mg	8.95	(S.O. 1499(E) dated 30.03.2022)	7.85	Per Tablet
28	6.4.10	Levofloxacin	Tablet750mg	12.14	(S.O. 1499(E) dated 30.03.2022)	10.69	Per Tablet
29	6.4.11	Linezolid	Tablet600mg	36.69	(S.O. 1499(E) dated 30.03.2022)	31.81	Per Tablet
30	6.4.12	Moxifloxacin	Tablet400mg	28.13	(S.O. 1499(E) dated 30.03.2022)	22.79	Per Tablet
31	6.4.15	Rifampicin	Capsule600mg	12.87	(S.O. 1499(E) dated 30.03.2022)	10.13	Per Capsule
32	6.5.3	Fluconazole	Tablet400mg	34.69	(S.O. 1499(E) dated 30.03.2022)	26.53	Per Tablet
33	6.7.1.1	Abacavir	Tablet300 mg	52.36	(S.O. 1499(E) dated 30.03.2022)	43.34	Per Tablet
34	6.7.1.2	Abacavir (A) +Lamivudine(B)	Tablet600mg(A)+300mg(B)	101.18	(S.O. 1499(E) dated 30.03.2022)	64.5	Per Tablet
35	6.7.2.2	Nevirapine	Tablet200 mg	15.89	(S.O. 1499(E) dated 30.03.2022)	14.09	Per Tablet
36	6.7.3.2	Raltegravir	Tablet400mg	173.77	(S.O. 1499(E) dated 30.03.2022)	131.81	Per Tablet
37	6.7.4.2	Darunavir	Tablet600mg	185.33	(S.O. 1499(E) dated 30.03.2022)	137.73	Per Tablet
38	6.8.2	Entecavir	Tablet1mg	140.76	(S.O. 1499(E) dated 30.03.2022)	116.15	Per Tablet
39	6.8.4	Sofosbuvir	Tablet400mg	741.12	(S.O. 1499(E) dated 30.03.2022)	468.32	Per Tablet
40	6.10.1.5	Clindamycin	Capsule150mg	16.07	(S.O. 1499(E) dated 30.03.2022)	14.59	Per Capsule
41	6.10.1.5	Clindamycin	Capsule300mg	26.24	(S.O. 1499(E) dated 30.03.2022)	25.3	Per Capsule
42	5.2.1.2	Flunarizine	Tablet5mg	3.06	(S.O. 1499(E) dated 30.03.2022)	2.21	Per Tablet
43	5.2.1.2	Flunarizine	Tablet10mg	5.26	(S.O. 1499(E) dated 30.03.2022)	4.3	Per Tablet
44	5.3.1	Levodopa (A) +Carbidopa(B)	Tablet 100 mg (A) + 25 mg (B)	2.5	(S.O. 1499(E) dated 30.03.2022)	2.3	Per Tablet
45	5.3.1	Levodopa (A) +Carbidopa(B)	Tablet 100 mg (A) + 10 mg (B)	1.73	(S.O. 1499(E) dated 30.03.2022)	1.57	Per Tablet
46	5.3.1	Levodopa (A) +Carbidopa(B)	Tablet250mg(A) +25mg(B)	4.15	(S.O. 1499(E) dated 30.03.2022)	3.94	Per Tablet

S.No	Section of revised Schedule-I	Formulation	Dosage form(s) and strength(s)	Prevailing Ceiling Price		New Ceiling Price With immediate effect	Unit
(1)	(2)	(3)	(4)	Rs./Unit	SO No. & dated	(7)	(8)
				(5)	(6)		
47	10.1.3	Isosorbidedinitrate	Tablet5mg	0.83	(S.O. 1499(E) dated 30.03.2022)	0.73	Per Tablet
48	10.3.1	Amlodipine	Tablet2.5mg	1.84	(S.O. 1499(E) dated 30.03.2022)	1.59	Per Tablet
49	10.3.1	Amlodipine	Tablet5mg	2.89	(S.O. 1499(E) dated 30.03.2022)	2.23	Per Tablet
50	10.3.1	Amlodipine	Tablet10mg	5.63	(S.O. 1499(E) dated 30.03.2022)	4.81	Per Tablet
51	10.3.5	Ramipril	Tablet2.5 mg	5.53	(S.O. 1499(E) dated 30.03.2022)	4.65	Per Tablet
52	10.3.5	Ramipril	Tablet 5mg	8.7	(S.O. 1499(E) dated 30.03.2022)	7.3	Per Tablet
53	10.3.7	Telmisartan	Tablet20mg	4.05	(S.O. 1499(E) dated 30.03.2022)	3.44	Per Tablet
54	10.3.7	Telmisartan	Tablet40mg	7.32	(S.O. 1499(E) dated 30.03.2022)	6.03	Per Tablet
55	10.3.7	Telmisartan	Tablet80mg	11.15	(S.O. 1499(E) dated 30.03.2022)	9.24	Per Tablet
56	18.3.1.6	Metformin	Tablet1000mg	4	(S.O. 1499(E) dated 30.03.2022)	3.11	Per Tablet
57	18.3.1.6	Metformin	Tablet500mg	2.13	(S.O. 1499(E) dated 30.03.2022)	1.77	Per Tablet
58	18.3.1.1	Glimepiride	Tablet2mg	6.34	(S.O. 1499(E) dated 30.03.2022)	5.11	Per Tablet
59	18.3.1.1	Glimepiride	Tablet1mg	3.99	(S.O. 1499(E) dated 30.03.2022)	3.27	Per Tablet
60	5.4.1	Donepezil	Tablet10mg	17.82	(S.O. 1499(E) dated 30.03.2022)	15.24	Per Tablet
61	5.4.1	Donepezil	Tablet5mg	12.48	(S.O. 1499(E) dated 30.03.2022)	10.57	Per Tablet
62	10.6.1	Atorvastatin	Tablet80mg	New	New	36.19	Per Tablet
63	10.6.1	Atorvastatin	Tablet40mg	21.42	(S.O. 1499(E) dated 30.03.2022)	16.92	Per Tablet
64	10.6.1	Atorvastatin	Tablet20mg	14.75	(S.O. 1499(E) dated 30.03.2022)	11.01	Per Tablet
65	10.6.1	Atorvastatin	Tablet10mg	6.09	(S.O. 1499(E) dated 30.03.2022)	4.38	Per Tablet
66	1.4.2	Baclofen	Tablet20mg	16.43	(S.O. 1499(E) dated 30.03.2022)	14.52	Per Tablet
67	1.4.2	Baclofen	Tablet10mg	11.94	(S.O. 1499(E) dated 30.03.2022)	10.39	Per Tablet
68	1.4.2	Baclofen	Tablet5mg	6.15	(S.O. 1499(E) dated 30.03.2022)	5.68	Per Tablet
69	18.6.2	Levothyroxine	Tablet 50mcg	1.1	(S.O. 1499(E) dated 30.03.2022)	0.92	Per Tablet
70	18.6.2	Levothyroxine	Tablet75mcg	1.44	(S.O. 1499(E) dated 30.03.2022)	1.28	Per Tablet
71	18.6.2	Levothyroxine	Tablet88mcg	1.71	(S.O. 1499(E) dated 30.03.2022)	1.47	Per Tablet
72	18.6.2	Levothyroxine	Tablet150mcg	1.72	(S.O. 1499(E) dated 30.03.2022)	1.59	Per Tablet
73	18.6.2	Levothyroxine	Tablet112mcg	1.6	(S.O. 1499(E) dated 30.03.2022)	1.48	Per Tablet
74	18.6.2	Levothyroxine	Tablet25mcg	1.45	(S.O. 1499(E) dated 30.03.2022)	1.29	Per Tablet
75	18.3.1.6	Metformin	ModifiedreleaseTablet1000mg	4.05	(S.O. 1499(E) dated 30.03.2022)	3.52	Per Tablet
76	1.4.5	Vecuronium	Powderforinjection10mg	209.93	(S.O. 1499(E) dated	104.67	Each

S.No (1)	Section of revised Schedule-I (2)	Formulation (3)	Dosage form(s) and strength(s) (4)	Prevailing Ceiling Price		New Ceiling Price With immediate effect (7)	Unit (8)
				Rs./Unit (5)	SO No. & dated (6)		
77	1.4.5	Vecuronium	Powderforinjection 4 mg	101.32	(S.O. 1499(E) dated 30.03.2022)	66.36	Each vial
78	7.1.10	Capecitabine	Tablet500mg	140.33	(S.O. 1499(E) dated 30.03.2022)	100.53	Per Tablet
79	22.1.4	Misoprostol	Tablet200mcg	18.54	(S.O. 1499(E) dated 30.03.2022)	16.92	Per Tablet
80	26.4	Cholecalciferol	Solid oral dosage form 1000 IU Tablet	4.16	(S.O. 1499(E) dated 30.03.2022)	3.84	Per Tablet
81	6.2.2.2	Cefuroxime	Oralliquid125mg/5mL(p)	New	New	4.71	Per ML
82	7.4.11	Mesna	Injection100mg/mL	18.62	(S.O. 1499(E) dated 30.03.2022)	13.83	Per ML
83	2.1.4	Mefenamicacid	Oralliquid100mg/5mL(p)	0.58	(S.O. 1499(E) dated 30.03.2022)	0.5	Per ML
84	6.7.1.3	Lamivudine	Tablet100mg	New added	New added	9.28	Per Tablet
85	6.7.1.3	Lamivudine	Tablet150mg	New added	New added	9.69	Per Tablet
86	6.5.5	Itraconazole	Oralliquid10mg/mL	New added	New added	4.41	Per ML
87	7.4.7	Haloperidol	Tablet1.5mg	1.84	(S.O. 1499(E) dated 30.03.2022)	1.37	Per Tablet
88	7.4.7	Haloperidol	Tablet5mg	3.82	(S.O. 1499(E) dated 30.03.2022)	3.18	Per Tablet
89	23.1.3	Haloperidol	Tablet10mg	4.9	(S.O. 1499(E) dated 30.03.2022)	4.26	Per Tablet
90	7.2.1	Bicalutamide	Tablet50mg	76.18	(S.O. 1499(E) dated 30.03.2022)	38.62	Per Tablet
91	7.2.2	Letrozole	Tablet2.5mg	39.03	(S.O. 1499(E) dated 30.03.2022)	26.15	Per Tablet
92	7.3.3	Mycophenolatemoetil	Tablet500mg	91.19	(S.O. 1499(E) dated 30.03.2022)	65.89	Per Tablet
93	23.2.1.1	Amitriptyline	Tablet50mg	6.45	(S.O. 1499(E) dated 30.03.2022)	5.34	Per Tablet
94	5.2.1.1	Amitriptyline	Tablet75mg	6.23	(S.O. 1499(E) dated 30.03.2022)	4.77	Per Tablet
95	8.2.2	Heparin	Injection1000IU/mL	24.39	(S.O. 2151(E) dated 30.06.2020)	18.92	Per ML
96	8.2.2	Heparin	Injection5000IU/mL	60.54	(S.O. 2151(E) dated 30.06.2020)	53.48	Per ML
97	5.2.1.1	Amitriptyline	Tablet25mg	2.5	(S.O. 1499(E) dated 30.03.2022)	2.16	Per Tablet
98	7.4.6	Fluoxetine	Capsule20 mg	4.05	(S.O. 1499(E) dated 30.03.2022)	3.56	Per Capsule
99	23.2.1.3	Fluoxetine	Capsule60 mg	10.87	(S.O. 1499(E) dated 30.03.2022)	9.9	Per Capsule
100	23.2.1.3	Fluoxetine	Capsule40 mg	6.15	(S.O. 1499(E) dated 30.03.2022)	5.79	Per Capsule
101	23.2.1.3	Fluoxetine	Capsule10 mg	3.3	(S.O. 1499(E) dated 30.03.2022)	2.96	Per Capsule
102	7.3.4	Tacrolimus	Capsule0.5mg	24.56	(S.O. 1499(E) dated 30.03.2022)	18.43	Per Capsule
103	7.3.4	Tacrolimus	Capsule1mg	43.38	(S.O. 1499(E) dated	36.23	Per

S.No	Section of revised Schedule-I	Formulation	Dosage form(s) and strength(s)	Prevailing Ceiling Price		New Ceiling Price With immediate effect	Unit
				Rs./Unit	SO No. & dated		
				(1)	(2)	(3)	(4)
					30.03.2022)		Capsule
104	7.3.4	Tacrolimus	Capsule2mg	84.97	(S.O. 1499(E) dated 30.03.2022)	75.22	Per Capsule
105	7.1.34	Temozolomide	Capsule20 mg	662.24	(S.O. 1499(E) dated 30.03.2022)	393.6	Per Capsule
106	7.1.34	Temozolomide	Capsule250mg	5203.58	(S.O. 1499(E) dated 30.03.2022)	3838.48	Per Capsule
107	23.3.2	Zolpidem	Tablet5mg	5.98	(S.O. 1499(E) dated 30.03.2022)	5.44	Per Tablet
108	23.3.2	Zolpidem	Tablet10mg	9.38	(S.O. 1499(E) dated 30.03.2022)	7.59	Per Tablet
109	6.6.2.1	Valganciclovir	Tablet450 mg	New added	New added	357.39	Per Tablet
110	7.1.28	Lenalidomide	Capsule5mg	New added	New added	59.98	Per Capsule
111	24.1.5	Montelukast	Tablet4 mg	New added	New added	8.95	Per Tablet
112	24.1.5	Montelukast	Tablet5 mg (including chewable tablets)	New added	New added	10.45	Per Tablet
113	24.1.5	Montelukast	Tablet10 mg	New added	New added	14.66	Per Tablet
114	6.8.1	Daclatasvir	Tablet60mg	New added	New added	178.34	Per Tablet
115	7.4.9	Loperamide	Tablet2mg	2.19	(S.O. 1499(E) dated 30.03.2022)	2.03	Per Tablet
116	23.1.4	Risperidone	Tablet1 mg	3.42	(S.O. 1499(E) dated 30.03.2022)	2.66	Per Tablet
117	23.1.4	Risperidone	Tablet2 mg	5.47	(S.O. 1499(E) dated 30.03.2022)	4	Per Tablet
118	23.1.4	Risperidone	Tablet4 mg	11.1	(S.O. 1499(E) dated 30.03.2022)	6.56	Per Tablet
119	6.7.3.1	Dolutegravir	Tablet50mg	New added	New added	100.59	Per Tablet

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.

(Dr. Vinod Kotwal)
Member Secretary